Lactulose Mip

Lactulose, the active ingredient in Lactulose Mip, is an osmotic laxative presented as an oral preparation for oral use. It is employed to relieve constipation and to manage hepatic encephalopathy by reducing intestinal ammonia absorption in patients with liver disease.

GNH USA supplies Lactulose Mip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides regulatory documentation for import.

Lactulose is used in gastrointestinal and hepatic conditions where reduction of intestinal ammonia or promotion of bowel movements is required. - Constipation: softens stool and promotes regular bowel movements. - Hepatic encephalopathy: lowers colonic ammonia production to improve neurological symptoms. - Prevention of hepatic encephalopathy recurrence: maintains low ammonia levels to reduce episodes in chronic liver disease.

Lactulose may cause a range of gastrointestinal and systemic reactions, most of which are mild and dose‑related.

Common Side Effects: - Bloating: feeling of abdominal fullness. - Flatulence: increased intestinal gas. - Abdominal cramps: intermittent stomach pain. - Diarrhea: loose, watery stools. - Nausea: sensation of unease in the stomach.

Serious or Rare Side Effects: - Severe electrolyte imbalance: may lead to cardiac arrhythmias. - Dehydration: excessive fluid loss requiring medical attention. - Allergic reaction: rash, itching, swelling, or difficulty breathing.

When prescribing lactulose, clinicians should consider several safety aspects to minimize adverse outcomes. - Renal function: assess kidney status, especially in patients at risk of dehydration. - Electrolyte balance: monitor serum electrolytes during prolonged therapy. - Diabetes mellitus: use caution because lactulose solutions contain sugars. - Galactosemia: avoid use in patients with this metabolic disorder. - Concomitant laxatives: avoid combining with other strong laxatives to prevent severe diarrhea. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Lactulose can affect the pharmacokinetics or pharmacodynamics of several medicines; awareness of these interactions helps optimize therapy.

Major Interactions (Avoid): - Other osmotic or stimulant laxatives: may cause excessive fluid loss and electrolyte disturbances. - Antidiabetic agents: lactulose’s sugar content can potentiate hypoglycemia. - Mineral supplements (e.g., calcium, magnesium): may reduce lactulose efficacy by altering colonic pH.

Moderate Interactions (Monitor Closely): - Antibiotics that alter gut flora: may diminish lactulose’s conversion to acids, reducing its effect. - Proton pump inhibitors: potential impact on gastric emptying and colonic pH. - Oral electrolyte solutions: concurrent use may affect overall electrolyte balance.